<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>36(1)</volume><submitter>Anwar S</submitter><pubmed_abstract>Dysferlinopathies are debilitating autosomal recessive muscular dystrophies caused by mutations in the &lt;i>DYSF&lt;/i> gene, encoding dysferlin, a protein crucial for sarcolemmal homeostasis and membrane resealing. Currently, no therapies exist for dysferlinopathies. Dysferlin features a modular structure with multiple calcium-dependent C2 lipid-binding domains. Clinical reports of mild, late-onset phenotypes suggest partial retention of functionality despite missing C2 domains, supporting exon-skipping therapies using antisense oligonucleotides (ASOs). In this study, we identified a patient-derived muscle cell line with a splice site mutation in &lt;i>DYSF&lt;/i> intron 26, causing exon 26 exclusion, an out-of-frame transcript, and no detectable dysferlin protein. We hypothesized that skipping &lt;i>D</pubmed_abstract><journal>Molecular therapy. Nucleic acids</journal><pagination>102443</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC11834094</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Antisense oligonucleotide-mediated exon 27 skipping restores dysferlin function in dysferlinopathy patient-derived muscle cells.</pubmed_title><pmcid>PMC11834094</pmcid><pubmed_authors>Roshmi RR</pubmed_authors><pubmed_authors>Bigot A</pubmed_authors><pubmed_authors>Woo S</pubmed_authors><pubmed_authors>Haque US</pubmed_authors><pubmed_authors>Anwar S</pubmed_authors><pubmed_authors>Arthur Lee JJ</pubmed_authors><pubmed_authors>Duddy WJ</pubmed_authors><pubmed_authors>Maruyama R</pubmed_authors><pubmed_authors>Yokota T</pubmed_authors></additional><is_claimable>false</is_claimable><name>Antisense oligonucleotide-mediated exon 27 skipping restores dysferlin function in dysferlinopathy patient-derived muscle cells.</name><description>Dysferlinopathies are debilitating autosomal recessive muscular dystrophies caused by mutations in the &lt;i>DYSF&lt;/i> gene, encoding dysferlin, a protein crucial for sarcolemmal homeostasis and membrane resealing. Currently, no therapies exist for dysferlinopathies. Dysferlin features a modular structure with multiple calcium-dependent C2 lipid-binding domains. Clinical reports of mild, late-onset phenotypes suggest partial retention of functionality despite missing C2 domains, supporting exon-skipping therapies using antisense oligonucleotides (ASOs). In this study, we identified a patient-derived muscle cell line with a splice site mutation in &lt;i>DYSF&lt;/i> intron 26, causing exon 26 exclusion, an out-of-frame transcript, and no detectable dysferlin protein. We hypothesized that skipping &lt;i>D</description><dates><release>2025-01-01T00:00:00Z</release><publication>2025 Mar</publication><modification>2025-04-03T23:16:54.328Z</modification><creation>2025-04-03T23:16:54.328Z</creation></dates><accession>S-EPMC11834094</accession><cross_references><pubmed>39967852</pubmed><doi>10.1016/j.omtn.2024.102443</doi></cross_references></HashMap>